Moderna and Merck’s melanoma vaccine sales forecast to surpass $1 billion by 2031
Sales of US pharma companies Merck & Co (NYSE: MRK) and Moderna’s (Nasdaq: MRNA) personalized cancer vaccine intismeran autogene are projected to surpass $1 billion by 2031, following positive Phase III INTerpath-001 results in high-risk resected melanoma, reveals pharma intelligence platform GlobalData.
Intismeran autogene, given alongside Merck's Keytruda (pembrolizumab), met its primary endpoint of statistically-significant recurrence-free survival and its key secondary endpoint of distant-metastasis-free survival. Earlier this year, five-year follow-up Phase II data had shown a 49% reduction in the risk of recurrence or death for the combination versus pembrolizumab alone.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze